Skip to main content

Virios Therapeutics, Inc. (VIRI)

NASDAQ: VIRI · IEX Real-Time Price · USD
4.28 -0.08 (-1.83%)
Oct 26, 2021 4:00 PM EDT - Market closed
Market Cap36.40M
Revenue (ttm)n/a
Net Income (ttm)-16.56M
Shares Out8.33M
EPS (ttm)-2.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume38,108
Open4.33
Previous Close4.36
Day's Range3.99 - 4.59
52-Week Range3.99 - 16.71
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About VIRI

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.

IndustryBiotechnology
IPO DateDec 17, 2020
Employees3
Stock ExchangeNASDAQ
Ticker SymbolVIRI
Full Company Profile

Financial Performance

Financial Statements

News

Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination

ATLANTA--(BUSINESS WIRE)---- $VIRI #Antiviral--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debil...

1 month ago - Business Wire

Virios Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilit...

1 month ago - Business Wire

Virios Therapeutics Announces New Social Media Profiles

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic...

2 months ago - Business Wire

Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome ...

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic...

2 months ago - Business Wire

Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic...

2 months ago - Business Wire

Virios Therapeutics to Present at the SNN Network Summer Virtual Conference

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic...

2 months ago - Business Wire

Virios Therapeutics Featured in Bloomberg TV Interview

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic...

2 months ago - Business Wire

Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August ...

ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic...

2 months ago - Business Wire

Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Tr...

ATLANTA--(BUSINESS WIRE)---- $VIRI #fibromyalgia--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain an...

3 months ago - Business Wire

Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia Trial

Virios Therapeutics Inc (NASDAQ: VIRI) has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia. The disease is ch...

4 months ago - Benzinga

Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the ...

ATLANTA--(BUSINESS WIRE)---- $VIRI #IASP2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated...

4 months ago - Business Wire

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

4 months ago - Business Wire

Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the ...

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

4 months ago - Business Wire

Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

5 months ago - Business Wire

Virios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

5 months ago - Business Wire

Virios Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on Thursday, May 13, ...

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

5 months ago - Business Wire

Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

ATLANTA--(BUSINESS WIRE)--Interview with Chairman and CEO of Virios Therapeutics, Inc. to Air on Bloomberg Television on the RedChip Money Report

6 months ago - Business Wire

Virios Therapeutics to Present at the Needham Virtual Healthcare Conference

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

6 months ago - Business Wire

Virios Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

7 months ago - Business Wire

Virios Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Thu...

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

7 months ago - Business Wire

Virios Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in March 2021

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally trigge...

8 months ago - Business Wire

7 Stocks With Insider Buying

Insider buying could be a bullish signal for a stock. Why? The insiders may sell for a number of reasons.

8 months ago - InvestorPlace

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal im...

8 months ago - Business Wire

Virios Therapeutics to Present at the BIO CEO & Investor Conference

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal im...

8 months ago - Business Wire

Virios Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

ATLANTA--(BUSINESS WIRE)--Virios Therapeutics, Inc. (VIRI) will present at the H.C. Wainwright Virtual BioConnect Conference, taking place January 11-14, 2021.

9 months ago - Business Wire